Viracta Therapeutics, Inc.

VIRX · OTC
Analyze with AI
9/30/2024
6/30/2024
3/31/2024
12/31/2023
Operating Activities
Net Income-$10,553-$9,830-$9,141-$13,765
Dep. & Amort.-$575$96$110$123
Deferred Tax$0$0$0-$1,950
Stock-Based Comp.$1,251$1,376$1,837$1,784
Change in WC$1,564-$1,246-$318$2,306
Other Non-Cash$1,220-$223$1,750$1,475
Operating Cash Flow-$7,093-$9,827-$7,849-$10,027
Investing Activities
PP&E Inv.$0$0$0$0
Net Acquisitions$0$0$0-$180
Inv. Purchases-$3,490-$3,586-$6,057-$7,480
Inv. Sales/Matur.$11,650$15,289$20,249$16,750
Other Inv. Act.$0$0$14,192$9
Investing Cash Flow$8,160$11,703$14,192$9,270
Financing Activities
Debt Repay.-$1,921-$1-$6,678$0
Stock Issued-$44$44$80$172
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0$44$0$46
Financing Cash Flow-$1,921$43-$6,598$218
Forex Effect$0$0$0$0
Net Chg. in Cash-$854$1,919-$255-$539
Supplemental Information
Beg. Cash$13,981$12,062$12,317$12,856
End Cash$13,127$13,981$12,062$12,317
Free Cash Flow-$7,093-$9,827-$7,849-$10,027
Viracta Therapeutics, Inc. (VIRX) Financial Statements & Key Stats | AlphaPilot